Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
69 hedge funds and large institutions have $181M invested in Albireo Pharma Inc in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 10 closing their positions.
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
7% less funds holding
Funds holding: 74 → 69 (-5)
39% less capital invested
Capital invested by funds: $298M → $181M (-$117M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
80% less call options, than puts
Call options by funds: $80K | Put options by funds: $410K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$3.03M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.75M |
| 3 |
Goldman Sachs
New York
|
+$778K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$770K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$755K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$6.26M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.39M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.48M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.05M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.29M |
ALBO Hedge Fund Activity: Q3 2019 in Review
69 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2019, worth a combined $181M — down 39% from $298M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALBO and 6 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 33 added.
The largest buyer was Victory Capital Management, adding an estimated $3.03M. The largest seller was Fosun International, exiting entirely with an estimated $6.26M sold.
- 69 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2019, down from 74 in Q2 2019.
- Funds reported $181M of Albireo Pharma Inc stock for Q3 2019, down 39% quarter-over-quarter.
- 6 funds opened new Albireo Pharma Inc positions in Q3 2019 and 10 closed out, a net change of -4 holders.
- The largest Albireo Pharma Inc buyer in Q3 2019 was Victory Capital Management, an estimated $3.03M added.
- The largest Albireo Pharma Inc seller in Q3 2019 was Fosun International, an estimated $6.26M sold.
Based on aggregated 13F filings for Q3 2019.